• 1
    Talley NJ, Jones M, Nuyts G, Dubois D. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 2003; 98: 110711.
    Direct Link:
  • 2
    Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 7509.
    Direct Link:
  • 3
    Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98: 24549.
    Direct Link:
  • 4
    Whitehead WE. Psychosocial aspects of functional gastrointestinal disorders. Gastroenterol Clin North Am 1996; 25: 2134.
  • 5
    Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 4052.
  • 6
    Bouin M, Plourde V, Boivin M et al. Rectal distension testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 17717.
  • 7
    Munakata J, Naliboff B, Harraf F et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997; 112: 5563.
  • 8
    Dickhaus B, Mayer EA, Firooz N et al. Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol 2003; 98: 13543.
    Direct Link:
  • 9
    Layer P, Keller J, Loeffler H, Kreiss A. Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. Ther Clin Risk Manag 2007; 3: 10718.
  • 10
    Crowell D, Harris LA, DiBaise JK, Olden KW. Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. Curr Opin Invest Drugs 2007; 8: 6670.
  • 11
    Currie MG, Fok KF, Kato J et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA 1992; 89: 94751.
  • 12
    Hamra FK, Forte LR, Eber SL et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA 1993; 90: 104648.
  • 13
    Forte LR, Freeman RH, Krause WJ, London RM. Guanylin peptides: cyclic GMP signaling mechanisms. Braz J Med Biol Res 1999; 32: 132936.
  • 14
    Nakazato M, Yamaguchi H, Kinoshita H et al. Identification of biologically active and inactive human uroguanylins in plasma and urine and their increases in renal insufficiency. Biochem Biophys Res Commun 1996; 220: 58693.
  • 15
    Field M, Graf LH Jr, Laird WJ, Smith PL. Heat-stable enterotoxin of Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine. Proc Natl Acad Sci USA 1978; 75: 28004.
  • 16
    Vaandrager AB, Smolenski A, Tilly BC et al. Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl-channel activation. Proc Natl Acad Sci USA 1998; 95: 146671.
  • 17
    Andresen V, Camilleri M, Busciglio IA et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007; 133: 7618.
  • 18
    Johnston JM, Kurtz CB, Drossman DA et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009; 104: 12532.
  • 19
    Busby RW, Bryant AP, Cordero EA et al. The molecular target of MDE-1100 is a guanylate cyclase C (GC-C), an apical receptor on intestinal epithelial cells. Gastroenterology 2005; 128(Suppl. 2): A-464.
  • 20
    Hachet T, Caussette M. A multifunction and programmable computerized barostat. Gastroenterol Clin Biol 1993; 17: 34751.
  • 21
    Morteau O, Hachet T, Caussette M, Bueno L. Experimental colitis alters visceromotor response to colorectal distension in awake rats. Dig Dis Sci 1994; 39: 123948.
  • 22
    Williams CL, Villar RG, Peterson JM, Burks TF. Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome. Gastroenterology 1988; 94: 61121.
  • 23
    Schwetz I, Bradesi S, McRoberts JA et al. Delayed stress-induced colonic hypersensitivity in male Wistar rats: role of neurokinin-1 and corticotropin-releasing factor-1 receptors. Am J Physiol 2004; 286: G68391.
  • 24
    Gecse K, Róka R, Ferrier L et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008; 57: 5919.
  • 25
    Larsson MH, Rapp L, Lindstrom E. Effect of DSS-induced colitis on visceral sensitivity to colorectal distension in mice. Neurogastroenterol Motil 2006; 18: 14452.
  • 26
    Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005; 3: 71725.
  • 27
    Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patient-asseseed illness in irritable bowel syndrome. Am J Gastroenterol 2008; 103: 253643.
    Direct Link:
  • 28
    Camilleri M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol Motil 2005; 17: 3116.
  • 29
    Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 2637.
  • 30
    Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196201.
  • 31
    Bryant AP, Busby R, Cordero EA et al. MD-1100, a therapeutic agent in development for the treatment of IBS-C, enhances intestinal secretion and transit, decreases visceral pain and is minimally absorbed in rats. Gastroenterology 2005; 128(Suppl. 2): A-464.
  • 32
    Marcus CS, Lengemann FW. Use of radioyttrium to study food movement in the small intestine of the rat. J Nutr 1962; 76: 17982.
  • 33
    Forte LR, Thorne PK, Eber SL et al. Stimulation of intestinal Cl transport by heat-stable enterotoxin: activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 1992; 263: C60715.
  • 34
    Zaccolo M, Movsesian MA. A cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 2007; 100: 156978.
  • 35
    Johnston JM, Macdougall JE, Lavins BJ et al. Linaclotide significantly improved abdominal pain/discomfort and global assessments in adults with irritable bowel syndrome with constipation. Neurogastroenterol Motil 2008; 20: 13 (OP37).
  • 36
    Agostini S, Eutamene H, Broccardo M et al. Peripheral anti-nociceptive effect of nociceptin/orphanin FQ in inflammation and stress-induced colonic hyperalgesia in rats. Pain 2009; 141: 2929.
  • 37
    Rolfe V, Levin RJ. Enterotoxin Escherichia coli STa activates a nitric oxide-dependent myenteric plexus secretory reflex in the rat ileum. J Physiol 1994; 475: 5317.
  • 38
    Madsen GL, Knoop FC. Inhibition of the secretory activity of Escherichia coli heat-stable enterotoxin by indomethacin. Infect Immun 1978; 22: 1437.
  • 39
    Beubler E, Badhri P, Schirgi-Degen A. 5-HT receptor antagonists and heat-stable Escherichia coli enterotoxin-induced effects in the rat. Eur J Pharmacol 1992; 219: 44550.
  • 40
    McLean PG, Picard C, Garcia-Villar R et al. Role of kinin B1 and B2 receptors and mast cells in post intestinal infection-induced hypersensitivity to distension. Neurogastroenterol Motil 1998; 6: 49908.
  • 41
    La JH, Kim TW, Sung TS, Kim HJ, Kim JY, Yang IS. Role of mucosal mast cells in visceral hypersensitivity in a rat model of irritable bowel syndrome. J Vet Sci 2004; 5: 31924.
  • 42
    Gue M, Del Rio-Lacheze C, Eutamene H, Theodorou V, Fioramonti J, Bueno L. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil 1997; 9: 2719.
  • 43
    Barreau F, Cartier C, Leveque M et al. Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay. J Physiol 2007; 580: 34756.
  • 44
    Coelho AM, Fioramonti J, Bueno L. Mast cell degranulation induces delayed rectal allodynia in rats: role of histamine and 5-HT. Dig Dis Sci 1998; 43: 72737.
  • 45
    Coelho AM, Vergnolle N, Guiard B, Fioramonti J, Bueno L. Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. Gastroenterology 2002; 122: 103547.
  • 46
    Bradesi S, Schwetz I, Ennes HS et al. Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia. Am J Physiol Gastrointest Liver Physiol 2005; 289: G4253.
  • 47
    Larauche M, Bradesi S, Million M et al. Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats. Am J Physiol Gastrointest Liver Physiol 2008; 294: G103340.